Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00849030 | ATAC - Arimidex, Tamoxifen Alone or in Combination | PHASE3 | COMPLETED | 9,358 | — | — | Jul 1, 1996 | Apr 1, 2010 | Jun 6, 2012 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Arimidex 1mg + Nolvadex placebo |
| 2 | ACTIVE_COMPARATOR | Arimidex placebo + Nolvadex 20mg |
| 3 | ACTIVE_COMPARATOR | Arimidex 1mg + Nolvadex 20mg |
| Name | Type | Description |
|---|---|---|
| Anastozole (Arimidex) | DRUG | 1mg, orally, once daily |
| Tamoxifen (Nolvadex) | DRUG | 20mg, orally, once daily |
| Anastozole (Arimidex) placebo | DRUG | 1mg, orally, once daily |
| Tamoxifen (Nolvadex) placebo | DRUG | 20mg, orally, once daily |
Inclusion Criteria: * Patients with histologically proven operable invasive breast cancer * Patients who have completed all primary surgery and chemotherapy (if given), and are candidates to receive hormonal adjuvant therapy * Women defined as post-menopausal Exclusion Criteria: * Patients in who...